Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Etiopurpurin, Tin
2. Snet2
3. Tin Etiopurpurin
4. Tin Etiopurpurin Dichloride
1. Tin Ethyl Etiopurpurin
2. Purlytin
3. Snet2
4. Rostaporfin [mi]
5. Rostaporfin [inn]
6. Rostaporfin [usan]
7. Snet-2
8. Rostaporfin [mart.]
9. 466g63qe7g
10. (oc-6-13)-dichloro(rel-ethyl(18r,19s)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-.kappa.n(sup 23), .kappa.n(sup 24), .kappa.n(sup 25), .kappa.n(sup 26))tin
11. Tin, Dichloro(rel-ethyl (18r,19s)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-.kappa.n23,.kappa.n24,.kappa.n25,.kappa.n26)-, (oc-6-13)-
12. Tin, Dichloro(rel-ethyl(18r,19s)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-.kappa.-n(sup 23),-.kappa.-n(sup 24),-.kappa.-n(sup 25),-.kappa.-n(sup 26))-, (oc-6-13)-
| Molecular Weight | 764.4 g/mol |
|---|---|
| Molecular Formula | C37H42Cl2N4O2Sn-4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 54.1 |
| Heavy Atom Count | 46 |
| Formal Charge | -4 |
| Complexity | 1050 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
Photosensitizing Agents
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)
Radiation-Sensitizing Agents
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)
ABOUT THIS PAGE
54
PharmaCompass offers a list of Rostaporfin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rostaporfin manufacturer or Rostaporfin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rostaporfin manufacturer or Rostaporfin supplier.
PharmaCompass also assists you with knowing the Rostaporfin API Price utilized in the formulation of products. Rostaporfin API Price is not always fixed or binding as the Rostaporfin Price is obtained through a variety of data sources. The Rostaporfin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rostaporfin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rostaporfin, including repackagers and relabelers. The FDA regulates Rostaporfin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rostaporfin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rostaporfin supplier is an individual or a company that provides Rostaporfin active pharmaceutical ingredient (API) or Rostaporfin finished formulations upon request. The Rostaporfin suppliers may include Rostaporfin API manufacturers, exporters, distributors and traders.
Rostaporfin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rostaporfin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rostaporfin GMP manufacturer or Rostaporfin GMP API supplier for your needs.
A Rostaporfin CoA (Certificate of Analysis) is a formal document that attests to Rostaporfin's compliance with Rostaporfin specifications and serves as a tool for batch-level quality control.
Rostaporfin CoA mostly includes findings from lab analyses of a specific batch. For each Rostaporfin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rostaporfin may be tested according to a variety of international standards, such as European Pharmacopoeia (Rostaporfin EP), Rostaporfin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rostaporfin USP).
